# Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Healthy Volunteers

> **NCT01489644** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 62 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** repaglinide
- **DRUG:** metformin
- **DRUG:** repaglinide and metformin combination tablet

## Key facts

- **NCT ID:** NCT01489644
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2006-07
- **Final completion:** 2006-07
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2017-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01489644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01489644, "Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Healthy Volunteers". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01489644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*